4//SEC Filing
Akinsanya Karen 4
Accession 0001808805-22-000033
CIK 0001808805other
Filed
Mar 30, 8:00 PM ET
Accepted
Mar 31, 6:16 PM ET
Size
6.1 KB
Accession
0001808805-22-000033
Insider Transaction Report
Form 4
Akinsanya Karen
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-03-30+105,998→ 105,998 totalExercise: $4.24Exp: 2032-03-30→ Common Stock (105,998 underlying)
Footnotes (1)
- [F1]In connection with the appointment of the Reporting Person to the Issuer's board of directors (the "Board") on March 30, 2022, the Reporting Person automatically received the Option (the "Initial Award") under the Issuer's Outside Director Compensation Policy and in accordance with the Issuer's 2021 Equity Incentive Plan (the "Plan"). Subject to the Reporting Person's continuous status as a "Service Provider" (as defined in the Plan), the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the Initial Award's grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). The grant date is March 30, 2022.
Documents
Issuer
Nautilus Biotechnology, Inc.
CIK 0001808805
Entity typeother
Related Parties
1- filerCIK 0001797672
Filing Metadata
- Form type
- 4
- Filed
- Mar 30, 8:00 PM ET
- Accepted
- Mar 31, 6:16 PM ET
- Size
- 6.1 KB